Newsroom
Discover the latest news and updates from Almirall.
Quick Links
Almirall press kit
PDF 2.4MB
Year in review 2024
PDF 2.7MB
Almirall at a glance
PDF 22.1MB
Discover the latest news and updates from Almirall.
Almirall press kit
PDF 2.4MB
Year in review 2024
PDF 2.7MB
Almirall at a glance
PDF 22.1MB
563 results
Published on 28 June 2026
As Pride Month comes to a close, we are reminded that the conversation around diversity, inclusion, and belonging should continue every day of the year. At Almirall, we believe that understanding the full patient experience means looking beyond the condition itself and recognizing the unique perspectives and identities that shape each person's journey.
To mark Pride Month, we talked to members of the LGBTQIA+ community who are living with Hidradenitis Suppurativa (HS) and are part of the HS Connect community. Through their personal reflections, Rae Adams, Destineé Spurrel, and Cassandra Stand share their experiences of identity, visibility, and living with a chronic condition.
Their stories highlight the importance of feeling seen, heard, and respected. They remind us that healthcare goes beyond physical symptoms and that supporting wellbeing requires listening to the diverse experiences of the people we serve.
At Almirall, our commitment to medical dermatology is rooted in a holistic approach to care—one that values every individual and fosters greater understanding, empathy, and inclusion. By amplifying patient voices and creating space for meaningful conversations, we can help build a more supportive future for everyone living with skin diseases.
Published on 25 June 2026
At Almirall, sustainability is a key part of how we create long-term value for patients, society, and the planet. We are proud to share that we have once again been included in the World’s Most Sustainable Companies 2026 ranking, compiled by TIME and Statista.
This year, we further strengthened our sustainability performance, improving our overall score from 65.8 to 72.2. This achievement reflects the steady progress we have made in implementing our sustainability strategy and embedding environmental, social, and governance principles across our business.
This recognition highlights the positive momentum of our Act4Impact strategy and the commitment of our teams to advancing responsible and sustainable practices throughout the organization. It also reinforces our belief that business success and sustainable growth go hand in hand.
As we continue our journey, we remain focused on creating a lasting positive impact—driving innovation in medical dermatology while contributing to a healthier and more sustainable future for all.
Thank you to everyone contributing to making sustainability a fundamental part of who we are and how we operate.
Published on 10 June 2026
Acne is one of the most common skin conditions worldwide, affecting millions of people across all ages and backgrounds. Yet, its impact extends far beyond the visible symptoms, often influencing self-confidence, emotional well-being, and daily life.
During Acne Awareness Month, we want to recognize the profound effect that acne and other dermatological conditions can have on those living with them. Behind every diagnosis is a unique personal journey, reminding us that skin health is about much more than what can be seen on the surface.
At Almirall, we are committed to advancing medical dermatology and deepening the scientific understanding of skin diseases. Equally important, we believe in listening to the real experiences of patients to help foster a more holistic approach to care—one that considers both physical and emotional wellbeing.
By increasing awareness and supporting the dermatology community, we aim to contribute to a future where people living with skin conditions feel understood, supported, and empowered throughout their journey.
Learn more about our commitment to holistic skin health and patient-centered care at:
https://www.almirall.com/patients
Published on 5 June 2026
At Almirall, improving the lives of patients goes hand in hand with protecting the environment we all share. This World Environment Day, we want to reinforce our commitment to taking decisive climate action on our path to becoming a net-zero emissions company by 2050.
But 2050 is built on the choices we make today. We are already making tangible progress through real, measurable actions. Our operational sites across Spain and Germany have been running on 100% renewable electricity since 2018, and in 2025 we reduced our direct greenhouse gas emissions by 22%, keeping us firmly on track to achieve our 50% reduction target by 2030.
We are also strengthening our approach to water management, having already reduced our consumption by 20% from our baseline, with the ambition to reach a 25% reduction by 2030. These efforts are helping us build greater resilience in the face of climate-related risks.
Our progress has been externally recognised, with Almirall named among Europe’s Climate Leaders 2026 by the Financial Times and Statista for the third consecutive year.
Every action we take brings us one step closer to a more sustainable future — for our patients, our communities and the planet we all share.
Published on 1 June 2026
During Hidradenitis Suppurativa Awareness Week, we want to shed light on a chronic, painful and often misunderstood condition that goes far beyond the skin. Hidradenitis suppurativa (HS) is a non-contagious inflammatory disease characterized by painful nodules, abscesses and, in some cases, scarring, which can significantly impact patients’ quality of life and daily routines.
Beyond its physical symptoms, HS carries a substantial emotional and psychological burden. Persistent pain, together with stigma and a lack of awareness, can affect sleep, confidence, mental health and overall well-being, often making the invisible impact of the disease as challenging as the visible one. For many people living with HS, managing the condition also means navigating uncertainty and the feeling of not being fully understood.
Raising awareness is essential to improving understanding, encouraging earlier diagnosis and reducing stigma. Greater knowledge of the disease can help patients seek the care they need and support a more timely and accurate diagnosis, while also fostering a more empathetic and informed society.
At Almirall, we remain committed to advancing innovation in medical dermatology and to developing solutions that make a meaningful difference for people living with HS, with a clear focus on addressing both the physical and emotional impact of the disease.
Published on 28 May 2026
We’re proud to be recognised for the third consecutive year as one of Europe’s Climate Leaders by the Financial Times and Statista. This recognition reflects the consistent effort we’ve made to turn environmental ambition into tangible results, embedding sustainability into the core of our business.
Over the past years, we have continued to strengthen how we measure and manage our environmental impact, integrating sustainability considerations across decision-making processes, operations, and innovation. This ongoing work allows us not only to track progress more effectively, but also to identify new opportunities to reduce our footprint and contribute positively to the communities and ecosystems we are part of.
Driving real progress means going beyond commitments—it requires measurable action, long-term vision, and continuous improvement. That’s why we remain focused on aligning our corporate strategy with science-based goals, ensuring that every step we take contributes to a more sustainable future.
This milestone is not just about recognition, but about reinforcing our responsibility to keep moving forward.
Published on 24 May 2026
On AK Global Day, we launched Skin Scouts, a global awareness initiative designed to reinforce the importance of early detection in medical dermatology. The campaign encourages everyone to look closer at their skin and recognize early warning signs that often go unnoticed, helping transform awareness into timely and meaningful action.
Actinic keratosis is a common condition that can act as an early warning sign of skin cancer. Too often, these lesions are mistaken for harmless skin changes linked to ageing or sun exposure. That is why, on AK Global Day, we proudly launch the #AKSkinScouts initiative to remind people that paying attention early can make a critical difference for long-term skin health.
Built around three simple steps — observe, detect, and act — Skin Scouts aims to empower the general public with practical knowledge. The campaign encourages regular skin observation, greater awareness of rough or scaly patches in sun-exposed areas, and a better understanding of key risk factors such as chronic sun exposure and skin type.
By combining education, awareness, and a clear call to action, Skin Scouts promotes a proactive approach to skin health and shared responsibility. Through engaging content and simple gestures, the initiative invites everyone to sharpen their focus, join the movement, and help spread a message that can lead to earlier detection and better outcomes.
Published on 18 May 2026
Press release
PDF 329.3KB
Published on 11 May 2026
Press release
PDF 209.9KB
Published on 11 May 2026
Today, we shared our financial results for the first quarter of 2026, continuing our positive trajectory and delivering performance in line with expectations and our long-term growth strategy.
This first quarter marks another step forward in our growth journey, supported by the strong momentum of our European Dermatology business, which grew by 19.3% year-on-year, reaching €166.3 MM. Overall, total Net Sales increased by 2.2% year-on-year to €291 MM, representing a 9% increase on a last twelve months (LTM) basis. These results reflect the consistency of our performance and the strength of the foundations we continue to build.
Our growth continues to be driven by the solid performance of our biologics portfolio and the sustained contribution of our broader dermatology portfolio, reinforcing our position in medical dermatology and supporting long-term value creation.
Profitability also showed a positive evolution, with total EBITDA reaching €67.5 MM, representing 23.2% of Net Sales and an improvement compared to the previous year. This reflects our ongoing focus on operational efficiency and disciplined execution across the business.
During the quarter, we also continued to advance our R&D pipeline, reinforcing our commitment to long-term innovation. Key milestones included the initiation of a new Phase I study and the announcement of a new strategic R&D collaboration, further strengthening our scientific capabilities and future growth potential.
Looking ahead, we remain focused on executing our strategy and sustaining our growth momentum. Our outlook for the full year 2026 remains unchanged, with expected Net Sales growth of 9–12% and EBITDA in the range of €270 MM to €290 MM.
As we continue to deliver on our strategy, we remain committed to transforming today’s science into meaningful solutions for people living with skin conditions.
